Lausanne, Switzerland – December 1, 2010 – Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs that target unmet medical needs, today announced that it received the “2010 Frost & Sullivan European Biopharmaceuticals Company of the Year Award”. This Award is presented each year to the company that has excelled in the following criteria: growth strategy excellence, growth implementation excellence, degree of innovation with products and technologies and leadership in customer value.
It is a great honour to be recognised by such a highly respected business research and consulting firm. Receiving this award is a great encouragement for us as we continually search for innovative, cutting edge technologies for the development of tomorrow’s novel effective therapeutics. Debiopharm’s partners support the development activities of the Group and are thus part of the Award.
– Dr Rolland-Yves Mauvernay, President and founder of Debiopharm Group
Debiopharm has successfully developed five products that are currently on the market, namely Eloxatin®/Elplat® for the treatment of colorectal cancer, Decapeptyl®/Trelstar®/Pamorelin® 1-month, 3-month and 6-month formulation for the treatment of advanced prostate cancer, endometriosis, precocious puberty, in vitro fertilisation programmes, uterine fibroids, and Moapar®/Salvacyl® for the treatment of severe sexual deviations.
Debiopharm’s main asset is its 300 highly skilled employees. However just as essential is the company’s financial independence, a shelter from short term financial objectives. Top management is stable and predictable, meaning that continuity is guaranteed. Debiopharm is committed to innovation and presents each year various Awards to recognise and encourage new ideas and technologies. These include the Debiopharm Life Sciences Award delivered at the EPFL, Lausanne, Switzerland; the JCA-Mauvernay Award (in Japan) and the Debiopharm / Valais Life Sciences Award (in Valais, Switzerland).
Debiopharm is also devoted to giving back to community by promoting health and education through humanitarian actions such as “Kantuta Association” that provides basic care and schooling for deprived children of the streets of Sucre, Bolivia; les “Pinceaux Magiques” an association that entertains sick children in Swiss hospitals by giving them the opportunity to paint on silk; and by supporting the adventurer Sarah Marquis in her 20’000 km eXplorAsia walk from Siberia to Australia.
About Debiopharm Group
Debiopharm Group (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses, develops and/or co-develops promising biological and small molecule drug candidates having reached clinical development phases I, II or III. Debiopharm is also prepared to consider earlier stage candidates. It develops its products for global registration and maximum commercial potential. The products are out-licensed to pharmaceutical partners for sales and marketing. Besides drug development, Debiopharm Group embarked a few years ago in the field of companion diagnostics with a view to progressing in the area of personalised medicine.
Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.
For more information on Debiopharm Group, please visit: www.debiopharm.com
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company’s Growth Partnership Service provides the CEO and the CEO’s Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 40 offices on six continents. For more information, please visit: www.awards.frost.com